Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer

Meaghan L. Khan, Thorvardur R. Halfdanarson, Mitesh J Borad

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is an aggressive disease with dismal outcomes despite recent advances using combination chemotherapeutic regimens. The lack of an adequate immune response to malignant cells has been identified as a factor associated with tumor aggressiveness and refractoriness to systemic treatment. Preclinical and early clinical studies have identified numerous immunotherapeutic and oncolytic viral therapeutic strategies aimed towards amplifying the immune reaction to pancreatic cancer and have established encouraging results. Promising antitumor efficacy has been observed both in vitro and in vivo with many of these approaches. These novel applications have also led to improved understanding of the process of pancreatic tumor growth and invasion, knowledge of the tumor microenvironment and have pioneered further investigations of similar therapies. Here we review both immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1255-1275
Number of pages21
JournalFuture Oncology
Volume10
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Pancreatic Neoplasms
Tumor Microenvironment
Neoplasms
Adenocarcinoma
Therapeutics
Growth

Keywords

  • immunotherapy
  • oncolytic viral
  • pancreatic cancer
  • vaccine therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. / Khan, Meaghan L.; Halfdanarson, Thorvardur R.; Borad, Mitesh J.

In: Future Oncology, Vol. 10, No. 7, 2014, p. 1255-1275.

Research output: Contribution to journalArticle

Khan, Meaghan L. ; Halfdanarson, Thorvardur R. ; Borad, Mitesh J. / Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. In: Future Oncology. 2014 ; Vol. 10, No. 7. pp. 1255-1275.
@article{e88e97e1fe2b46abb77751223f2b5c0a,
title = "Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer",
abstract = "Pancreatic adenocarcinoma is an aggressive disease with dismal outcomes despite recent advances using combination chemotherapeutic regimens. The lack of an adequate immune response to malignant cells has been identified as a factor associated with tumor aggressiveness and refractoriness to systemic treatment. Preclinical and early clinical studies have identified numerous immunotherapeutic and oncolytic viral therapeutic strategies aimed towards amplifying the immune reaction to pancreatic cancer and have established encouraging results. Promising antitumor efficacy has been observed both in vitro and in vivo with many of these approaches. These novel applications have also led to improved understanding of the process of pancreatic tumor growth and invasion, knowledge of the tumor microenvironment and have pioneered further investigations of similar therapies. Here we review both immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.",
keywords = "immunotherapy, oncolytic viral, pancreatic cancer, vaccine therapy",
author = "Khan, {Meaghan L.} and Halfdanarson, {Thorvardur R.} and Borad, {Mitesh J}",
year = "2014",
doi = "10.2217/fon.13.277",
language = "English (US)",
volume = "10",
pages = "1255--1275",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer

AU - Khan, Meaghan L.

AU - Halfdanarson, Thorvardur R.

AU - Borad, Mitesh J

PY - 2014

Y1 - 2014

N2 - Pancreatic adenocarcinoma is an aggressive disease with dismal outcomes despite recent advances using combination chemotherapeutic regimens. The lack of an adequate immune response to malignant cells has been identified as a factor associated with tumor aggressiveness and refractoriness to systemic treatment. Preclinical and early clinical studies have identified numerous immunotherapeutic and oncolytic viral therapeutic strategies aimed towards amplifying the immune reaction to pancreatic cancer and have established encouraging results. Promising antitumor efficacy has been observed both in vitro and in vivo with many of these approaches. These novel applications have also led to improved understanding of the process of pancreatic tumor growth and invasion, knowledge of the tumor microenvironment and have pioneered further investigations of similar therapies. Here we review both immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

AB - Pancreatic adenocarcinoma is an aggressive disease with dismal outcomes despite recent advances using combination chemotherapeutic regimens. The lack of an adequate immune response to malignant cells has been identified as a factor associated with tumor aggressiveness and refractoriness to systemic treatment. Preclinical and early clinical studies have identified numerous immunotherapeutic and oncolytic viral therapeutic strategies aimed towards amplifying the immune reaction to pancreatic cancer and have established encouraging results. Promising antitumor efficacy has been observed both in vitro and in vivo with many of these approaches. These novel applications have also led to improved understanding of the process of pancreatic tumor growth and invasion, knowledge of the tumor microenvironment and have pioneered further investigations of similar therapies. Here we review both immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.

KW - immunotherapy

KW - oncolytic viral

KW - pancreatic cancer

KW - vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=84903198479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903198479&partnerID=8YFLogxK

U2 - 10.2217/fon.13.277

DO - 10.2217/fon.13.277

M3 - Article

C2 - 24947264

AN - SCOPUS:84903198479

VL - 10

SP - 1255

EP - 1275

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 7

ER -